Clinical trial
An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
NCT03712787 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
- Lead sponsor
- AbbVie
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- March 22, 2019
- Completion date
- September 30, 2021
- Enrollment
- 364 (actual)
- Sites
- 57
Conditions
As the registry lists them; a condition with its own page is linked.
alzheimer's disease